InicioAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
11,66 $
Después del cierre:(0,00 %)0,00
11,66 $
Cerrados: 22 nov, 20:00:00 GMT-5 · USD · NASDAQ · Renuncia de responsabilidad
Cierre anterior
11,66 $
Intervalo diario
11,53 $ - 12,22 $
Intervalo anual
10,41 $ - 19,09 $
Cap. bursátil
1122,51 M USD
Volumen medio
1,35 M
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos | 50,02 M | 613,22 % |
Gastos operativos | 44,20 M | 5,21 % |
Ingresos netos | -2,62 M | 92,76 % |
Margen de beneficio neto | -5,25 | 98,98 % |
Beneficios por acción | -0,03 | 92,68 % |
EBITDA | 708,00 mil | 102,05 % |
Tipo impositivo efectivo | -3,47 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 65,81 M | -57,04 % |
Activos totales | 158,25 M | -22,08 % |
Responsabilidades totales | 83,59 M | -10,07 % |
Patrimonio total | 74,66 M | — |
Acciones en circulación | 96,36 M | — |
Precio-valor contable | 14,95 | — |
Rentabilidad económica | -0,52 % | — |
Retorno sobre capital | -0,73 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -2,62 M | 92,76 % |
Efectivo de operaciones | -6,89 M | 81,98 % |
Efectivo de inversión | 4,93 M | -49,80 % |
Efectivo de financiación | 1,18 M | -96,14 % |
Variación neta del flujo de caja | -265,00 mil | -114,51 % |
Flujo de caja libre | -9,99 M | 64,96 % |
Información sobre la empresa
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Director ejecutivo
Fundación
1990
Sitio web
Empleados
154
